CAMBRIDGE, Mass., June 14 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX - News), a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases today announced results of the voting at its 2006 Annual Meeting of Stockholders, which was held today. At the meeting, shareholders voted in favor of all proposals that were put forth in the company’s proxy statement -- electing all nominees for director, each of whom previously served on the company’s board of directors, and ratifying the selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm.
